N-cyclononyl-3-formamido-2-hydroxybenzamide | 1379608-92-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-cyclononyl-3-formamido-2-hydroxybenzamide
• CAS: 1379608-92-0
• 化学式: C₁₇H₂₄N₂O₃
• 分子量: 304.389
• InChiKey: DRNPWCBKGYRDSE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  78.4
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  环壬酮 在 palladium on activated charcoal 、 氢气 、 sodium cyanoborohydride 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成 N-cyclononyl-3-formamido-2-hydroxybenzamide
  参考文献：
  名称：

  [EN] INHIBITORS OF THE ACTIVITY OF COMPLEX III OF THE MITOCHONDRIAL ELECTRON TRANSPORT CHAIN AND USE THEREOF FOR TREATING DISEASES
  [FR] INHIBITEURS DE L'ACTIVITÉ DU COMPLEXE III DE LA CHAÎNE MITOCHONDRIALE DE TRANSFERT DES ÉLECTRONS ET UTILISATION DE CEUX-CI POUR TRAITER DES MALADIES

  摘要：

  公开号：

  WO2012070015A9

文献信息

• INHIBITORS OF THE ACTIVITY OF COMPLEX III OF THE MITOCHONDRIAL ELECTRON TRANSPORT CHAIN AND USE THEREOF FOR TREATING DISEASES
  申请人：Clement-Schatlo Virginie

  公开号：US20140051678A1

  公开（公告）日：2014-02-20

  The present invention relates to compounds which are inhibitors of the activity of Complex III of the mitochondrial electron transport chain and pharmaceutical compositions comprising said compounds alone or in combination with other active agents. The present invention further relates to use of the compounds of the invention as medicaments or as agrochemicals where their properties as inhibitors of the mitochondrial respiration is of benefit. More particularly the present invention relates to the use of the compounds of the invention in a method of treating and/or preventing cancers presenting tumor-initiating cells. (Formula I) (I)
• USE OF MITOCHONDRIAL ACTIVITY INHIBITORS FOR THE TREATMENT OF POOR PROGNOSIS ACUTE MYELOID LEUKEMIA
  申请人：UNIVERSITÉ DE MONTRÉAL

  公开号：US20190192488A1

  公开（公告）日：2019-06-27

  A method for treating acute myeloid leukemia (AML), such as poor risk AML, by administering to a subject in need en thereof an effective amount of a mitochondrial activity inhibitor, for example a class A electron transport chain (ETC) complex I inhibitor such as Mubritinib or a pharmaceutically acceptable salt thereof, is disclosed. The AML to be treated may be characterized by certain features, such as high level of expression of one or more Homeobox (HOX)-network genes, high and/or low expression of specific genes, the presence of one or more cytogenetic or molecular risk factors such as intermediate cytogenetic risk, Normal Karyotype (NK), mutated NPM1, mutated CEBPA, mutated FLT3, mutated DNMT3A, mutated TET2, mutated IDH1, mutated IDH2, mutated RUNX1, mutated WT 1, mutated SRSF2, intermediate cytogenetic risk with abnormal karyotype (intern(abnK)), trisomy 8 (+8) and/or abnormal chromosome (5/7), and/or a high leukemic stem cell (LSC) frequency.
• [EN] INHIBITORS OF THE ACTIVITY OF COMPLEX III OF THE MITOCHONDRIAL ELECTRON TRANSPORT CHAIN AND USE THEREOF FOR TREATING DISEASES<br/>[FR] INHIBITEURS DE L'ACTIVITÉ DU COMPLEXE III DE LA CHAÎNE MITOCHONDRIALE DE TRANSFERT DES ÉLECTRONS ET UTILISATION DE CEUX-CI POUR TRAITER DES MALADIES
  申请人：STEMERGIE BIOTECHNOLOGY SA

  公开号：WO2012070015A9

  公开（公告）日：2012-07-19